40 registrations that name probiotics as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 40 registrations
Status
Phase
4US sites across 4 states
1
2 to 4
5 to 19
20 or more
All 40 registrations
RecruitingNCT05178069
LGG Supplementation in Patients With AUD and ALD
Phase 2
University of Louisville
About 60 people
Started Jun 1, 2022
In plain words A Phase 2 study of probiotics in people 21 to 65, run by University of Louisville. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 21 to 65. Conditions: Alcohol Use Disorder; Alcohol-associated Liver Disease.
Breath alcohol concentration (BAC) equal to 0.00 when the participant signs the informed consent document.
Age between 21 and 65 years old (inclusive).
Willingness to receive trial treatment.
Ability to provide informed consent
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
: Placebo for Probiotic; Lactobacillus Rhamnosus GG
Registered summary
To test the efficacy of 6-month LGG compared to placebo in treating Alcoholic Use Disorder (AUD) and liver injury in Alcoholic Hepatitis (AH). And to evaluate the effects of LGG treatment compared to placebo on therapeutic-mechanistic markers of the gut-brain axis and pro-inflammatory activity in patients with AUD and moderate AH
Where, as registered
1 US site in 1 state.
RecruitingNCT05517928
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
No phase
Mayo Clinic
About 30 people
Started Mar 3, 2023
In plain words A study of probiotics in people 18 and older, run by Mayo Clinic. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older; healthy volunteers accepted. Conditions: Healthy.
Individuals on an unrestricted regular diet with no dietary restrictions (vegan, low FODMAP, gluten free, dairy-free etc) or other fad diets (e.g., keto, intermittent fasting, etc.).
Healthy subjects will be screened for current or chronic GI symptoms using a 16-item questionnaire.
Only those with an absence of symptoms will eligible to participate.
The exclusion criteria are on the listing.
What it tests, as registered
Omeprazole; Lactobacillus rhamnosus GG; Placebo
Registered summary
The purpose of this study is to investigate the impact of the probiotic Lactobacillus rhamnosus (LGG) on proton pump inhibitor (PPI)-induced changes to the microbes that live in the gastrointestinal tract and are passed out in the stool. PPI medicines reduce stomach acid and are commonly used to treat acid reflux disease.
Where, as registered
1 US site in 1 state.
RecruitingNCT07139366
Saccharomyces Boulardii Combined With Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Treatment
Phase 4
Yongquan Shi
About 1,248 people
Started Oct 28, 2025
In plain words A Phase 4 study of probiotics in people 18 to 75, run by Yongquan Shi. It plans to enroll about 1,248 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Gastritis; Dyspepsia; Helicobacter Pylori Infection; Gastric Cancer; Peptic Ulcer.
Age between 18~75, both gender.
Patients who had failed H.pylori eradication therapies .
Women are eligible if they are not pregnant or nursing, and if they are of childbearing potential they are required to use medically acceptable contraception for the duration of the study and 30 days thereafter.
This study aims at evaluating efficacy and safety of Saccharomyces boulardii combined with bismuth-containing quadruple Therapy versus bismuth-containing quadruple Therapy(bismuth#esomeprazole#tetracycline and furazolidone) in H. pylori rescue therapy. It is hypothesized that Saccharomyces boulardii combined with bismuth-containing quadruple Therapy is superior to bismuth-containing quadruple Therapy. Patients with confirmed failure of H. pylori eradication will be randomized to one of the treatments described above. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07168434
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
Phase 3
Biocodex
About 406 people
Started Oct 22, 2025
In plain words A Phase 3 study of probiotics in people 18 to 65, run by Biocodex. It plans to enroll about 406 people at 10 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: IBS (Irritable Bowel Syndrome); IBS-D (Diarrhea-predominant); IBS, Mixed Symptoms.
Male or female aged ≥ 18 and ≤ 65 years.
Diagnosis of IBS of any subtype, except constipation predominant (IBS-C), according to Rome IV criteria.
IBS-SSS total score ≥ 175 at inclusion.
Able and willing to maintain their nutrition habits throughout the study participation.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Saccharomyces Boulardii 250 MG; Placebo 250 mg
Registered summary
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of Saccharomyces boulardii CNCM I-745 on global IBS symptoms, measured by the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), in comparison to placebo after 8 weeks. The full summary is on the listing.
Where, as registered
No US site; Spain (8), Portugal (2).
RecruitingNCT06938464
Preventive Effect of Probiotics in GDM
No phase
Women's Hospital School Of Medicine Zhejiang University
About 334 people
Started Oct 27, 2023
In plain words A study of probiotics in female participants 18 to 50, run by Women's Hospital School Of Medicine Zhejiang University. It plans to enroll about 334 people at 1 site, none in the US.
Pregnant women who meet the high-risk indicators for GDM and agree to participate in this study.
included between 12-16 gestational weeks
A woman was considered high risk when her pre-pregnancy BMI ≥ 24 kg/m\^2, having family history of diabetes (type 1 or 2), GDM or PCOS (polycystic ovary syndrome) history, history of delivering macrosomia or stillbirth, or glucose in urine…
The exclusion criteria are on the listing.
What it tests, as registered
Probiotics; Placebo
Registered summary
Gut microbiota is instrumental in the microbial and metabolic network of pregnant women, and is potentially related with gestational diabetes. Perinatal probiotic intervention contributes to improved glucose regulation during pregnancy. Our randomized, double-centered, placebo-controlled study is planned to recruit 334 pregnant women who is in high risk for gestational diabetes. They will be assumed randomly probiotic powder per day or placebo from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th gestational weeks. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07333313
Study of Oral Uremic Toxin Absorbent/Probiotics to Modulate Systemic Inflammation and Retard the Progression of Chronic Kidney Disease in Patients With Diabetes.
No phase
National Taiwan University Hospital
About 300 people
Started Dec 31, 2024
In plain words A study of probiotics in people 20 and older, run by National Taiwan University Hospital. It plans to enroll about 300 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: Oral Uremic Toxin Absorbent.
Age > 20 years old but not pregnant on the day of screening.
DKD patients with stable renal function (Cre elevation < 0.3 mg/dL for at least 30 days) and PCS level (fluctuation < 10% for at least 30 days)
Group 1: 120 DKD patients with 45<eGFR<60 ml/min/1.73m2 in stable status. Group 2: 120 DKD patients with 30<eGFR<45 ml/min/1.73m2 in stable status.
Diabetes mellitus (DM) is a chronic inflammatory disease characterized by insufficient insulin secretion or insulin resistance, leading to hyperglycemia. Chronic inflammation and immune system dysfunction are characteristic of DM and can produce a plethora of cytokines and chemokines, thereby contributing to diabetic complications such as cardiovascular events and diabetic vasculopathy in DM. Besides, about 25% of people with diabetes eventually develop diabetic kidney disease (DKD). The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT05652621
Efficacy of Probiotics in Patients With IBD
No phase
The First Affiliated Hospital of Xinxiang Medical College
About 200 people
Started Jul 31, 2022
In plain words A study of probiotics in people 18 to 80, run by The First Affiliated Hospital of Xinxiang Medical College. It plans to enroll about 200 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Ulcerative Colitis; Irritable Bowel Syndrome.
Clinical diagnosis of ulcerative colitis
Clinical diagnosis of irritable bowel
Can swallow probiotic pellets as required
The exclusion criteria are on the listing.
What it tests, as registered
probiotics
Registered summary
This research group plans to take patients with mild to moderate UC and diarrhea IBS diagnosed in the First Affiliated Hospital of Xinxiang Medical College as examples, and divide them into UC group and IBS group; Each group was randomly divided into two groups, namely, conventional treatment+probiotics group and conventional treatment+probiotics placebo group.Starting from the intervention of probiotics on intestinal flora to alleviate intestinal injury caused by UC and IBS patients, the indicators of intestinal flora, serum inflammatory factors, metabolites in vivo, intestinal… The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07470645
Effects of Probiotic Supplementation on Stress and Anxiety in Students
No phase
Nordic Biotic Sp. z o.o.
About 200 people
Started Apr 20, 2026
In plain words A study of probiotics in people 18 to 40, run by Nordic Biotic Sp. z o.o.. It plans to enroll about 200 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 40. Conditions: Stress; Anxiety; Sleep; Gastro-intestinal Symptoms in Healthy Subjects.
Male or female students aged 18-40 years
At least moderate stress (DASS-21 Stress score ≥10)
Mild anxiety (DASS-21 Anxiety score 6-13)
No clinical depression (DASS-21 Depression score ≤9)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Probiotics; Placebo
Registered summary
This randomized, double-blind, placebo-controlled study evaluates the efficacy and safety of an 8-week probiotic supplementation (Lactobacillus plantarum LP140 and Bifidobacterium breve BB010 in total daily dose 1 × 10¹⁰ CFU or matching placebo) in reducing perceived stress and anxiety, and improvement related psychological parameters in healthy university students during the examination period. The primary outcome is the change in Perceived Stress Scale (PSS-10) score at week 5 and week 8 of interevention compared to placebo. The full summary is on the listing.
Where, as registered
No US site; Poland (1).
RecruitingNCT04788914
lncRNAs as a Biomarker to Assess the Therapeutic Impact of Oral Absorbent ± Probiotics in CKD Patients With PAD
No phase
National Taiwan University Hospital
About 180 people
Started Apr 21, 2020
In plain words A study of probiotics in people 20 and older, run by National Taiwan University Hospital. It plans to enroll about 180 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: CKD; PAD.
Age > 20 years old on the day of screening.
CKD patients with eGFR 15 < eGFR < 60 ml/min/1.73m2 in a stable status, creatinine elevated less than 0.3 mg/dL in at least 30 days before enrollment.
Symptomatic PAD with Rutherford Stage ≥ 2 and ABI < 0.9 (or documented by CT-angio, vascular duplex, etc.).
Age > 20 years old on the day of screening.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Active bamboo charcoal± probiotics
Registered summary
Participants with chronic kidney disease (CKD) are at a higher risk of developing atherosclerotic peripheral artery disease (PAD). Retention of uremic toxins such as indoxyl sulfate (IS), p-cresyl sulfate (PCS) and trimethylamine N-oxide (TMAO) during CKD is detrimental to endothelial and vascular function and can predispose to the development and progression of PAD. Many of the uremic toxins originate from gut microbial metabolism. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT04792320
Oral Absorbent and Probiotics in CKD Patients With PAD on Gut Microbiota, IncRNA, Metabolome, and Vascular Function
No phase
National Taiwan University Hospital
About 180 people
Started Jun 19, 2020
In plain words A study of probiotics in people 20 and older, run by National Taiwan University Hospital. It plans to enroll about 180 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: CKD; PAD - Peripheral Arterial Disease.
Age > 20 years old on the day of screening.
CKD patients with eGFR 15 < eGFR < 60 ml/min/1.73m2 in a stable status, creatinine elevated less than 0.3 mg/dL in at least 30 days before enrollment.
Symptomatic PAD with Rutherford Stage ≥ 2 and ABI ≤ 0.9 (or documented by CT-angio, vascular duplex, etc.). II. non-CKD/PAD group Patients (Group II)
The exclusion criteria are on the listing.
What it tests, as registered
Active bamboo charcoal; probiotics
Registered summary
Taiwan has more chronic kidney disease (CKD) per capita than anywhere in the world, leading to the highest expense of National Health Insurance. By reviewing previous studies, uremic toxins contribute critically to the detrimental effects of CKD on atherosclerotic peripheral artery disease (PAD). When recognized early and managed appropriately, mortality and complications of the participants with CKD and established PAD can be minimized. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT04819217
Study of Oral Uremic Toxin Absorbent and Probiotics to Retard the Progression of Chronic Kidney Disease
No phase
National Taiwan University Hospital
About 180 people
Started May 1, 2020
In plain words A study of probiotics in people 20 and older, run by National Taiwan University Hospital. It plans to enroll about 180 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 20 and older. Conditions: CKD.
Age ≥ 20 years old on the day of screening.
CKD patients with eGFR 15 < eGFR <45 ml/min/1.73m2 and UACR > 100 mg/g in a stable status, creatinine elevated less than 0.3 mg/dL in at least 30 days before enrollment.
The exclusion criteria are on the listing.
What it tests, as registered
Active bamboo charcoal; Probiotics
Registered summary
In patients with chronic kidney disease (CKD), uremic toxins accumulate when kidney function declines. Those uremic toxins had a greater affinity to circulating proteins are called "protein bound uremic toxins, PBUT." Apart from traditional small or middle molecule uremic toxins, the PBUTs can be rarely eliminated using traditional renal replacement therapy, even using high flux dialysis modalities. Among these molecules identified, indoxyl sulfate (IS), and p-cresol (PC) are mostly studied. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT03773003
Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME)
No phase
Universität des Saarlandes
About 150 people
Started Jul 20, 2021
In plain words A study of probiotics in people 18 to 80, run by Universität des Saarlandes. It plans to enroll about 150 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80; healthy volunteers accepted. Conditions: Cancer Related Fatigue; Fatigue Syndrome, Chronic.
histologically, cytologically or radiologically confirmed tumor disease
indication for chemotherapy
Written consent to participation
The exclusion criteria are on the listing.
What it tests, as registered
Probiotics; Placebo
Registered summary
Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue Syndrome (CFS/ME) by Lipidomics, Metabolomics, Intestinal and Peritoneal Microbiome Analysis and Exome Analysis and Investigation of a Possible Benefit of Probiotics.
Where, as registered
No US site; Germany (1).
RecruitingNCT06595719
Multi-Strain Probiotics Supplementation With Standard Care in Mild to Moderate Ulcerative Colitis
No phase
National University of Malaysia
About 124 people
Started Feb 23, 2024
In plain words A study of probiotics in people 18 to 90, run by National University of Malaysia. It plans to enroll about 124 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 90. Conditions: Ulcerative Colitis.
Diagnosis of UC established by previous colonoscopy, with consistent histology, and clinical course.
UC involving at least the rectosigmoid, actively confirmed by colonoscopy at the beginning of the study.
Mild to moderate disease activity, defined as a PMS ranging from 3-8.
Use of medication at least 4 weeks prior to study.
The exclusion criteria are on the listing.
What it tests, as registered
Multi-Strain Probiotics; Placebo
Registered summary
Probiotics are one of the adjunctive treatments that have been extensively explored for Ulcerative colitis (UC) disease management. Probiotics, a group of beneficial bacteria, can bring various health benefits when adequately supplied to the body, especially for gut wellness. In particular, for UC patients, gut dysbiosis is one of the contributing factors in their pathogenesis. Thus, the supplementation of probiotics in combination with standard treatment can potentially help in relieving symptoms as well as promoting mucosal healing for long-term remission.
Where, as registered
No US site; Malaysia (1).
RecruitingNCT07047339
Evaluate the Efficacy and Safety of Probiotic 6600 as an Adjuvant Therapy for Colitis
Phase 2 and 3
Changhai Hospital
About 120 people
Starts Jul 1, 2025 (estimated)
In plain words A Phase 2 and 3 study of probiotics in people 18 to 75, run by Changhai Hospital. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Colitis; IBD (Inflammatory Bowel Disease); Probiotic Intervention.
Ulcerative colitis (UC) : met the clinical diagnostic criteria of UC "Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023, Xi 'an)", and modified Mayo score ≥4 points;
Crohn's disease (CD) : met the clinical diagnostic criteria of CD "Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (2023, Guangzhou)", and CDAI score ≥220;
Colitis: clinical diagnosis of colitis and modified SCCAI score ≥3; 3.
The age of signing the informed consent form was from 18 to 75 years old (including the cut-off value, male and female were not limited);
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Probiotics 6600; Placebo
Registered summary
This study was conducted in two phases. In Phase I, 40 UC participants, 40 CD participants, and 40 colitis participants were randomly assigned in a 1:1 ratio to the experimental group and the control group, respectively. The study included a screening period (1 week), a double-blind treatment period (24 weeks), an exit examination (1 day), and a safety follow-up period (4 weeks). The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07182942
The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease
Phase 4
Chujin Cao
About 120 people
Started Jun 7, 2024
In plain words A Phase 4 study of probiotics in people 18 to 75, run by Chujin Cao. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: CKD; Drug Effect.
Written informed consent was obtained;
ranging in age from 18 to 75 years;
CKD stage 3-5, that is, eGFR < 60 mL/min/1.73 m2 with non-dialysis stage, no dialysis indication, temporarily stable condition and drug control stage;
tolerance of Xiqing and probiotics treatment.
The exclusion criteria are on the listing.
What it tests, as registered
Xiqing; probiotics
Registered summary
Chronic kidney disease (CKD) has become a major public health problem worldwide. Patients with CKD are often accompanied by azotemia due to impaired renal function and excretion of nitrogen metabolic waste, which leads to multiple organ dysfunction, cardiac dysfunction and other complications. Therefore, it is an important strategy in the treatment of CKD to reduce the burden of kidney in CKD patients by removing nitrogen metabolic wastes in the body. Xiqing, which includes coated aldehyde oxystarch capsules, is a drug with adsorption effect. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT06448767
The Effect of a Multispecies Probiotics on Autism Symptoms in Children
No phase
Medical University of Warsaw
About 110 people
Started Aug 7, 2024
In plain words A study of probiotics in people 7 to 15, run by Medical University of Warsaw. It plans to enroll about 110 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 7 to 15. Conditions: Autism Spectrum Disorder.
Diagnosis of ASD according to the Diagnostic and Statistical Manual of Mental Disorders, the fifth edition (DSM-5) or International Classification of Diseases, Tenth Revision (ICD-10).
Children either not taking any medication or receiving the same medication for the last 2 months.
Patients, or their parents/caregivers, are willing to provide written informed consent, proceed with nutritional supplements throughout the 3-month trial, refrain from starting any kind of special diet for the duration of the study, and…
The exclusion criteria are on the listing.
What it tests, as registered
Multispecies probiotics; Placebo
Registered summary
In this trial, the investigators aim to evaluate the impact of a multispecies probiotic consisting of Bacillus subtilis W201, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus rhamnosus W140, Lactococcus lactis W19, Propionibacterium freudenreichii W200, on the severity of autism symptoms, quality of life, gastrointestinal symptoms, sleep disturbances, parental stress levels and urinary p-cresol concentrations in children with Autism Spectrum Disorder aged 7 to 15 years.
Where, as registered
No US site; Poland (3).
RecruitingNCT06074250
Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
Phase 2 and 3
The Canadian College of Naturopathic Medicine
About 100 people
Started Aug 15, 2024
In plain words A Phase 2 and 3 study of probiotics in female participants 18 to 43, run by The Canadian College of Naturopathic Medicine. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 43. Conditions: Perinatal Depression; PerinatalAnxiety.
Women 18-43 years old
12-35 weeks of gestation
Non-smoker/alcohol/recreational drug user
Financially stable
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Fish oil; Probiotics; Prebiotics; Diet Quality
Registered summary
Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies. The adverse outcomes extend beyond maternal well-being to long-term deficits in children and families. The gut-brain axis is a newly recognized key player in mental health disorders. Specifically, the microbial composition of the gut along with their metabolites are directly involved in disease onset and course. The full summary is on the listing.
Where, as registered
No US site; Canada (1).
RecruitingNCT07141888
The Effects of a Probiotic Food Supplement in Hyperuricaemia
No phase
Örebro University, Sweden
About 99 people
Started Dec 16, 2025
In plain words A study of probiotics in people 18 to 80, run by Örebro University, Sweden. It plans to enroll about 99 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Hyperuricemia With or Without Gout.
Signed informed consent prior to any study-related procedures
Age 18-80 years old
BMI range 17.5-40 kg/m2
Blood uric acid above 405 μmol/l (6.8 mg/dl)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Placebo (no active ingredient); Probiotics; Probiotics plus fibre
Registered summary
The overall aim of the project is to determine whether a daily intake of health-promoting bacteria, known as probiotics, with or without a dietary fiber, affects uric acid levels in individuals with elevated levels of uric acid in the blood (hyperuricemia). Additionally, the project will investigate which individuals benefit from this dietary supplement and which do not, based on factors such as gut microbiota composition and function, dietary habits, genetic factors, and inflammatory status. The ultimate goal is to develop a personalized therapy for hyperuricemia. The full summary is on the listing.
Where, as registered
No US site; Sweden (1).
RecruitingNCT06583720
Comparative Study Between Photodynamic Therapy with LED Associated with Probiotics in the Treatment of Halitosis
Phase 1
University of Nove de Julho
About 92 people
Started Nov 1, 2024
In plain words A Phase 1 study of probiotics in people 18 to 60, run by University of Nove de Julho. It plans to enroll about 92 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Halitosis.
Diagnosis of halitosis showing sulfhydride (SH2) ≥ 112 ppb in gas chromatography.
The exclusion criteria are on the listing.
What it tests, as registered
Oral hygiene at home; aPDT; Probiotics
Registered summary
Halitosis is a term that defines any odor or bad smell coming from the oral cavity, which can have a local or systemic origin. This project aims to verify if there is a difference in the effectiveness of treatment with antimicrobial photodynamic therapy (aPDT) with LED associated with treatment using probiotics in reducing halitosis. 92 participants, aged 18 to 60 years, diagnosed with halitosis, presenting sulfhydride (SH2) ≥ 112 ppb in gas chromatography will be selected. The full summary is on the listing.
Where, as registered
No US site; Brazil (1).
RecruitingNCT07605728
Probiotics for Abemaciclib-Induced Abdominal Discomfort.
Phase 2
Leeuwenhoek Laboratories Co. Ltd.
About 80 people
Starts May 15, 2026 (estimated)
In plain words A Phase 2 study of probiotics in people 18 and older, run by Leeuwenhoek Laboratories Co. Ltd.. It plans to enroll about 80 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Breast Cancer; Chemotherapy-induced Diarrhea.
Absolute Neutrophil Count (ANC) ≥ 1,500/μL without G-CSF support within 14 days of enrollment.
Platelet count ≥ 100,000/μL.
Hemoglobin ≥ 8.0 g/dL (red blood cell transfusion is permitted prior to enrollment).
Serum alkaline phosphatase (ALP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤ 3× the upper limit of normal.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Synbiotic supplement followed by Placebo; Placebo followed by Probiotics
Registered summary
This study aims to evaluate whether the addition of probiotics can help reduce abdominal discomfort (such as diarrhea) in breast cancer patients receiving Abemaciclib treatment. Abemaciclib is an effective targeted therapy but often causes gastrointestinal side effects. While Loperamide is the standard treatment for diarrhea, this study explores if probiotics can provide additional relief and improve metabolic health.Participants will be randomly assigned to receive either probiotics or a placebo alongside their standard care. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT07529457
Adults With Constipation
No phase
Wecare Probiotics Co., Ltd.
About 70 people
Started Jul 24, 2026
In plain words A study of probiotics in people 18 to 65, run by Wecare Probiotics Co., Ltd.. It plans to enroll about 70 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Constipation.
Men and women aged between 18 and 65 years;
Participants presenting with constipation, characterized by <3 spontaneous bowel movements per week or BSFS stool types 1-2;
Capable of following the study protocol and completing all required assessments; Individuals who have voluntarily signed the informed consent form;
No plans for pregnancy from at least 14 days prior to screening through 6 months after the study, with agreement to use reliable contraception methods.
The exclusion criteria are on the listing.
What it tests, as registered
Probiotics; Placebo
Registered summary
This randomized, double-blind, placebo-controlled trial will assess the clinical effects of probiotics in adults with functional constipation. Participants will receive probiotics or placebo for 8 weeks. The study will evaluate changes in bowel habits and symptom burden, as well as alterations in host inflammatory status, immune modulation, microbial ecosystem dynamics, neuroendocrine signaling related to the gut-brain axis, and systemic metabolic responses, to characterize the overall physiological impact of probiotic supplementation.
Where, as registered
No US site; China (1).
RecruitingNCT07094035
The Beneficial Effects on the Intestinal Function of a Food Supplement Based on an Extract of Green Tea and a Pool of Probiotics in Subjects With Irritable Bowel Syndrome With Predominance of Constipation
No phase
Adamas Biotech S.r.l.
About 64 people
Started Jul 30, 2025
In plain words A study of probiotics in people 18 to 70, run by Adamas Biotech S.r.l.. It plans to enroll about 64 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: IBS, Constipation Predominant.
aged between 18 and 70 years
able to understand and sign informed consent
HIV negative test
negative pregnancy test
9 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
food supplement based on a mixture of green tea extract and a pool of probiotics.; Placebo
Registered summary
The study will aim to evaluate the effectiveness of the use of a food supplement, based on a green tea extract (Camellia sinensis (L.) Kuntze - folium) and a pool of probiotics (L. plantarum, L. rhamnosus and B. animalis subsp. lactis), in the management of gastrointestinal distress in the general population and in subjects with IBS in the predominant form of IBS-C, with an impact on quality of life. The full summary is on the listing.
Where, as registered
No US site; Italy (1).
RecruitingNCT05791604
The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics
No phase
Children's Hospital of Fudan University
About 60 people
Started Apr 1, 2023
In plain words A study of probiotics in people 3 to 10, run by Children's Hospital of Fudan University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 3 to 10. Conditions: Prader-Willi Syndrome.
Pre-adolescent children with Prader Willi syndrome which were definitely diagnosed by gene testing.
Consistent with the diagnostic criteria for obesity.
Not participate in other research projects at present or three months before the research;
Agree to participate in the test and obtain the consent of their parents; voluntarily be the subjects and sign the informed consent form.
The exclusion criteria are on the listing.
What it tests, as registered
probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG; Prebiotics with galactomannan and oligofructose
Registered summary
Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. More and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children.
Where, as registered
No US site; China (1).
RecruitingNCT06765057
Effect of Probiotics "Psychobiotics" on Depression and Metabolic Syndrome in Saudi Arabia
Phase 2 and 3
Roaa Ahmed Alkreadees
About 60 people
Started Mar 2, 2025
In plain words A Phase 2 and 3 study of probiotics in people 18 to 65, run by Roaa Ahmed Alkreadees. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Depression Anxiety Disorder.
Major Depression Disorder (MDD) patients on antidepressants for at least 4 weeks or more.
MDD patients with pre-metabolic syndrome (at least 2 of the MetS components) and metabolic syndrome (at least 3 of the following components: central obesity with WC for men ≥ 94 centimeters while for women ≥ 80 centimeter, increased FPG ≥…
MDD patients with other comorbid diseases such as anxiety.
The goal of this clinical trial is to assess the effect of commercial multi-strains psychobiotics supplementation as an ad-on therapy on depressive symptoms and metabolic syndrome components (HDL-C, FPG, TGs, WC, BP) in adult depressed patients with pre-metabolic syndrome and metabolic syndrome. The second goal is to explore the effect of commercial multi-strains psychobiotics supplementation on the anthropometric measurement (weight, body mass index (BMI)) in adult depressed patients with pre-metabolic syndrome and metabolic syndrome. The full summary is on the listing.
Where, as registered
No US site; Saudi Arabia (1).
RecruitingNCT07046897
Analysis of the Gut Microbiota Composition After Consumption of Probiotic Bacteria
No phase
Lund University
About 60 people
Started Nov 12, 2024
In plain words A study of probiotics in people 18 to 65, run by Lund University. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65; healthy volunteers accepted. Conditions: Microbiota Analysis in Healthy Subjects.
You must be 18-65 years of age.
The exclusion criteria are on the listing.
What it tests, as registered
Consumption of probiotics strain 5; Consumption of probiotics strain 6
Registered summary
The goal of this intervention study is to evaluate the beneficial effect of the probiotic bacterium Bacillus coagulans in healthy volunteers. The main question it aims to answer is if the probiotic strains are modifying the microbiota composition in a beneficial way, evaluated in faecal- and saliva samples. Primary hypothesis: The probiotic bacteria will modify the microbiota composition in faecal- and saliva samples. Participants will consume the freeze-dried probiotic bacteria for 14 days. Before and after consumption, the participants will collect samples.
Where, as registered
No US site; Sweden (1).
RecruitingNCT07345455
Probiotics on Sperm Quality in Male Infertility Patients
No phase
Mackay Memorial Hospital
About 60 people
Started Sep 16, 2023
In plain words A study of probiotics in male participants 20 to 45, run by Mackay Memorial Hospital. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 20 to 45. Conditions: Male Infertility; Oligozoospermia; Asthenozoospermia; Teratozoospermia; Oligoasthenoteratozoospermia.
Males aged 20 to 45 years
Diagnosis of unexplained oligozoospermia, asthenozoospermia, or oligoasthenoteratozoospermia
Sperm concentration < 5 x 10\^6/mL
Sperm total motility < 40%
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Probiotics; Placebo
Registered summary
This randomized, placebo-controlled pilot study aims to evaluate the effects of probiotic supplementation on sperm quality in male patients diagnosed with infertility. Male infertility accounts for approximately 40% of all infertility cases and is closely related to abnormalities in sperm count, motility, and morphology. Factors such as oxidative stress, inflammation, and DNA fragmentation are known to impact sperm function and subsequent fertilization potential negatively. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
RecruitingNCT07213323
Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment
No phase
Hospices Civils de Lyon
About 50 people
Started Aug 5, 2026
In plain words A study of probiotics in people 18 to 75, run by Hospices Civils de Lyon. It plans to enroll about 50 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: Obesity &Amp; Overweight; Digestive Disorders.
Patient who is going to start a GLP-1 RA (semaglutide or tirzepatide) for weight management
Men or Women
BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 associated with one or more co-morbidities (arterial hypertension, sleep apnea, dyslipidemia, arthritis)
Between 18 and 75 years old
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Probiotics (Natural product); Placebo
Registered summary
Obesity is a prevalent chronic disease affecting 17% of the French population. Treatment involves multiple factors, with pharmacotherapy playing an increasingly important role. GLP-1 receptor agonists (GLP1 RAs) are considered revolutionary in obesity treatment, with three approved molecules available in France: liraglutide, semaglutide, and tirzepatide. These treatments, combined with a healthy lifestyle, induce significant weight loss: 9% with liraglutide, 15% with semaglutide, and 20% with tirzepatide. The full summary is on the listing.
Where, as registered
No US site; France (1).
RecruitingNCT06873165
Development of Microbial Therapeutics for Metabolic-associated Fatty Liver Disease: From Mechanistic Investigations to Clinical Trials
No phase
National Taiwan University Hospital
About 40 people
Started Jan 22, 2025
In plain words A study of probiotics in people 18 to 70, run by National Taiwan University Hospital. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease.
Male or female subjects aged between 20 and 70 years old.
The subject is diagnosed through FibroScan (CAP≧ 260 db/m)and meets one of below .
the subject's BMI ≧23 kg/m² or waist ≧ 90cm (male) 80cm (Female)
Fasting glucose≧100 mg/dL or sugar after meal ≧140 mg/dL or HbA1c≧5.7 or diagnosed type II diabetes(including under treatment or not)
6 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Probiotics; Placebo
Registered summary
The goal of this clinical trial is to investigate the efficacy and safety of pasteurized Akkermansia muciniphila strain NTUH\_Amuc03 (pAKK NTUH\_Amuc03) in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Patients. The main question it aims to answer is: Does pAKK NTUH\_Amuc03 trend to reduce the body weight, improve abnormal blood lipids , NASLD activity score, and HOMA-IR ? Researchers will compare pAKK NTUH\_Amuc03 to a placebo (a look-alike substance that contains no Akk) to see if pAKK NTUH\_Amuc03 works to MASLD. Participants will: 1. The full summary is on the listing.
Where, as registered
No US site; Taiwan (1).
Not yet recruitingNCT07643974
Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTD
Early phase 1
Medstar Health Research Institute
About 48 people
Starts Aug 2026 (estimated)
In plain words An early phase 1 study of probiotics in people 18 and older, run by Medstar Health Research Institute. It plans to enroll about 48 people at 2 US sites.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Gentamicin; Lactobacillus Rhamnosus GG
Registered summary
The main objective of the proposed research study is to determine in men and women with spinal cord injury/disease and neurogenic bladder whether the dose of coupled gentamicin \& Lactobacillus rhamnosus GG affects the recolonization of the bladder, and whether the rate of success differs by sex. Secondary objectives include determining whether that recolonization lasts 7, 14, or 28 days; and safety of the coupled gentamicin \& Lactobacillus instillations.
Where, as registered
2 US sites in 2 states.
Not yet recruitingNCT06827964
Practice of Nutrition Package in Myanmar
No phase
Tsinghua University
About 600 people
Starts Mar 10, 2025 (estimated)
In plain words A study of probiotics in people 7 to 15, run by Tsinghua University. It plans to enroll about 600 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 7 to 15; healthy volunteers accepted. Conditions: Malnutrition in Children.
Children and adolescents aged 7-15 years.
Residing in the local area for more than 1 year.
The exclusion criteria are on the listing.
What it tests, as registered
Soy-based Nutrition Package; Probiotics
Registered summary
The goal of this cluster randomized controlled trial is to study the effectiveness of the Nutrition Package (Yingyangbao) on improving malnutrition in children and adolescents aged 7-15 in Myanmar. The main questions it aims to answer are: * What is the effectiveness of Nutrition Package intervention on the growth, development, and nutritional health of children and adolescents aged 7-15 in Myanmar? * How safe and feasible is the Nutrition package? Researchers will compare the Nutrition Package plus probiotics, the Nutrition Package alone, and no intervention to see if the Nutrition Package… The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07012785
Efficacy Analysis of Saccharomyces Boulardii Combined With Minocycline in Treatment-naïve Patients With Helicobacter Pylori Infection
No phase
Zhongda Hospital
About 208 people
Starts Jun 2025 (estimated)
In plain words A study of probiotics in people 18 to 70, run by Zhongda Hospital. It plans to enroll about 208 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 70. Conditions: H. Pylori Infection.
Aged 18-70 years, regardless of gender;
Positive 13C/14C urea breath test result;
No previous history of H. pylori eradication treatment;
Agreement to participate in this study and signing of the informed consent form.
To assess the efficacy and safety of Saccharomyces boulardii combined with triple therapy containing minocycline in the initial eradication of Helicobacter pylori (H. pylori) infection
Where, as registered
No US site; China (1).
Not yet recruitingNCT07813182
Efficacy and Safety of Saccharomyces Boulardii in Treatment of Acute Diarrhea in Children Aged 6 Months to 5 Years Old
No phase
Can Tho University of Medicine and Pharmacy
About 206 people
Starts Aug 31, 2026 (estimated)
In plain words A study of probiotics in people 6 months to 60 months, run by Can Tho University of Medicine and Pharmacy. It plans to enroll about 206 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 months to 60 months; healthy volunteers accepted. Conditions: Acute Diarrhea.
Age from 6 months to 5 years old
Children are diagnosed with acute diarrhea according to WHO criteria.
The exclusion criteria are on the listing.
What it tests, as registered
Saccharomyces Boulardii Probiotic Supplement; The child will be treated with standard method
Registered summary
This study aimed to evaluate the effectiveness of saccharomyces-based treatment in children with acute diarrhea aged 6 months to 5 years compared to children treated with standard methods.
Where, as registered
No US site; Vietnam (1).
Not yet recruitingNCT07845253
Effect of Limosilactobacillus Reuteri on Social Deficits in Children With Autistic Spectrum Disorder
No phase
BioGaia AB
About 200 people
Starts Oct 15, 2026 (estimated)
In plain words A study of probiotics in people 4 to 12, run by BioGaia AB. It plans to enroll about 200 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 4 to 12. Conditions: Autism Spectrum Disorder.
Boys or girls aged between 4 to 12 years at screening.
ASD diagnosis confirmed by a qualified clinician according to DMS-5 criteria, M-CHAT used as a screening tool.
Parents/caregivers/legal guardians are ≥18 years.
Readiness and the opportunity for parents/caregivers/legal guardians to fill out a study diary, questionnaires, and report regularly during the intervention period.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Probiotics; Placebo
Registered summary
This is a double-blind, randomized, placebo-controlled, parallel-group study in children with Autism Spectrum Disorder (ASD) to evaluate the effect of a probiotic product on the ASD symptoms.
Where, as registered
No US site; Argentina (1).
Not yet recruitingNCT07870824
A Study to Investigate the Effect of Probiotics (L. Reuteri DSM 17938 and L. Reuteri DSM 33633) on Symptoms of Viral Upper Respiratory Tract Infections in Children
No phase
Milosevits Gergely
About 194 people
Starts Oct 12, 2026 (estimated)
In plain words A study of probiotics in people 4 to 17, run by Milosevits Gergely. It plans to enroll about 194 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 4 to 17. Conditions: Virus Diseases in Children.
Children with symptoms of upper respiratory tract infection (coughing/fever/sneezing/runny or congested nose/pharynx pain)
Any gender
Age from 4 years to 17 years
Signing a informed consent form by at least one parent, foster parent or guardian after patient information and by children aged over 6 years
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Probiotics (L. reuteri DSM 17938 and L. reuteri DSM 33633); Placebo
Registered summary
This study investigates the effect of Lactobacillus reuteri probiotic strains (DSM 17938 and L. reuteri DSM 33633) on symptoms of viral upper-respiratory tract infections in children.
Where, as registered
No US site; Hungary (1).
Not yet recruitingNCT06563921
RE and Probiotics in MAFLD/NAFLD
No phase
Nicolaus Copernicus University
About 180 people
Starts Apr 10, 2026 (estimated)
In plain words A study of probiotics in people 18 to 60, run by Nicolaus Copernicus University. It plans to enroll about 180 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: NASH; NAFLD; MAFLD.
Diagnosis of NAFLD/MAFLD or NASH (imaging or histological confirmation of fatty liver disease, e.g., ultrasound, MRI-PDFF, biopsy)
Age 18-60 years
Ability to understand the study procedures and provide informed consent.
Stable clinical condition for at least 3 months prior to study initiation.
This project aims to evaluate the roles of the autonomic nervous system (ANS) and gut microbiota as correlates of clinical improvement in metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD) in response to a therapeutic regimen comprising resistance exercise and probiotic supplementation. The primary objective is to investigate the effects of these non-pharmacological interventions on MAFLD/NAFLD and to identify patient phenotypes based on baseline ANS profiles and gut microbiota composition that predict clinical responses.
Where, as registered
No sites listed yet.
Not yet recruitingNCT06278688
Precision Probiotic Supplementation in Individuals With Mild Cognitive Impairment
No phase
National Yang Ming Chiao Tung University
About 120 people
Starts Mar 18, 2024 (estimated)
In plain words A study of probiotics in people 60 and older, run by National Yang Ming Chiao Tung University. It plans to enroll about 120 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 60 and older. Conditions: Mild Cognitive Impairment.
60 years old and above
Diagnosis of MCI based on 2011 NIA-AA criteria
Amyloid (+) measured by either amyloid PET imaging or CSF amyloid markers
No dietary supplements, including other probiotics, yogurts with live, active cultures or supplements, and immune-enhancing supplements in the past three months (or wash-out period for three months for individuals taking supplements)
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Precision probiotics
Registered summary
The overarching goal of this randomized-controlled trial is to investigate the role and mechanism of the microbiota-gut-brain axis in MCI. The main questions it aims to answer are: Aim 1: To investigate the association between gut microbiota, MCI and AD biomarkers. Investigators plan to compare gut microbiota profiles in a well-characterized cohort between individuals with MCI and cognitively normal adults using metagenomics sequencing data. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07025980
Effect of Sinbiotic With Multispecies Probiotics on Liver Parameters Liver Enzymes, Ultrasound, Elastography and Adipokines in Same Cases) in Patients With Metabolic Associated Steatotic Liver Disease.
Phase 2
Eva Cubric
About 114 people
Starts Jul 1, 2025 (estimated)
In plain words A Phase 2 study of probiotics in people 18 to 75, run by Eva Cubric. It plans to enroll about 114 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 75. Conditions: MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis); Diabetes Mellitus; Hypertension; Hyperlipidaemia.
MASLD confirmed by ultrasound and elastography with CAP > 260 dB/m/MHz;
other causes of chronic liver disease excluded and/or diagnosis confirmed by liver biopsy,
presence of metabolic syndrome according to the definition of the International Diabetes Federation (IDF): waist circumference for women over 80 cm or over 94 cm for men, and at least two of the other criteria (treated hypertensive or…
signed informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
The test product is a ready-to-use sinbiotic preparation of multispecies probiotics, ca-butyrate and FOS; Placebo Drug
Registered summary
Scientific hypothesis: the use of a synbiotic preparation with a multi-strain probiotic in patients with MASLD can lead to a decrease in non-invasive elastographic parameters of hepatic steatosis and fibrosis and an improvement in liver function. The main objective of this study is to examine whether the test product affects the improvement of liver function measured by elastographic parameters or at least the prevention of further disease progression. The full summary is on the listing.
Where, as registered
No US site; Croatia (1).
Not yet recruitingNCT06972524
Effects of Milk Probiotics Intervention on Blood Glucose Control Middle-aged and Elderly People With Pre-diabetes
No phase
Huilian Zhu
About 110 people
Starts Dec 1, 2025 (estimated)
In plain words A study of probiotics in people 40 to 75, run by Huilian Zhu. It plans to enroll about 110 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 75; healthy volunteers accepted. Conditions: Pre-biabetes.
Age between 40 and 75 years, regardless of gender.
Impaired fasting glucose (5.6 mmol/L ≤ FPG < 6.9 mmol/L) or glycated hemoglobin (HbA1c) between 5.7-6.4% (39-47 mmol/mol).
Resided in Guangzhou for the past six months and no plans to relocate or travel outside the city in the next month.
Signed informed consent form and voluntarily agreed to participate in the project.
The exclusion criteria are on the listing.
What it tests, as registered
a special probiotics from Mengniu Group, supplemented with milk powder; regular milk powder does not contain any additional supplementation, and the color, flavor, shape, taste, and weight are same with the probiotic milk powder
Registered summary
This study aims to conduct a 8-week probiotics intervention involving for middle-aged and elderly individuals with pre-diabetes, assessing its impact on blood glucose control in comparison to placebo
Where, as registered
No sites listed yet.
Not yet recruitingNCT07785206
Effectiveness of Saccharomyces Boulardii in Prevention of Antibiotic Associated Diarrhea
No phase
University of Child Health Sciences and Children's Hospital, Lahore
About 88 people
Starts Sep 2026 (estimated)
In plain words A study of probiotics in people 6 months to 5, run by University of Child Health Sciences and Children's Hospital, Lahore. It plans to enroll about 88 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 6 months to 5. Conditions: Antibiotic Associated Diarrhea; Upper Respiratory Tract Infection.
Children aged 6 months to 5 years presenting with upper respiratory tract infection (URTI)
Prescribed standard oral co-amoxiclav therapy
Both male and female patients
Written informed consent provided by parents or legal guardians
The exclusion criteria are on the listing.
What it tests, as registered
Co-amoxiclav; Saccharomyces boulardii
Registered summary
Antibiotic-associated diarrhea (AAD) is a common adverse effect in pediatric patients receiving broad-spectrum antibiotics such as co-amoxiclav for upper respiratory tract infections (URTI). This study aims to evaluate the effectiveness of the probiotic Saccharomyces boulardii in preventing antibiotic-associated diarrhea among children aged 6 months to 5 years receiving co-amoxiclav. Participants will be randomly allocated to receive either standard co-amoxiclav therapy alone or co-amoxiclav combined with Saccharomyces boulardii for 5 days. The full summary is on the listing.
Where, as registered
No US site; Pakistan (1).
Not yet recruitingNCT07568964
Evaluation of Probiotics' Effect on Atrial Fibrillation Recurrence in Patients Undergoing Cardioversion
No phase
Ain Shams University
About 56 people
Starts May 10, 2026 (estimated)
In plain words A study of probiotics in people 40 and older, run by Ain Shams University. It plans to enroll about 56 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 and older. Conditions: Atrial Fibrillation (AF).
Female or male aged 40 years or above with BMI less than 40
Persistent AF patients directly after cardioversion
The exclusion criteria are on the listing.
What it tests, as registered
Anticoagulant Therapy; Probiotics capsules
Registered summary
The aim of this clinical study is to evaluate the efficacy and tolerability of probiotics on atrial fibrillation recurrence.